Are Peptides Legal in the US? A 2026 Guide for Clinicians

Yes, many peptides are legal in the United States. Whether a particular peptide is legal depends on the route it takes to the patient. An FDA-approved peptide drug prescribed by a licensed clinician is legal. A compounded peptide is legal when the pharmacy and the bulk ingredient both qualify under federal and state law. A peptide sold online as "research use only" is not legal to market or use as a drug for people, whatever the label says.

The word "peptide" covers insulin, semaglutide, collagen in a protein shake, and unlabeled vials from a website. Federal law treats each of those differently, so the useful question is which pathway a given product uses. This guide covers each pathway, the controlled substance question, the 2026 FDA developments behind headlines about peptides "being legalized," and the state rules people search for most.

Status as of October 5, 2026. FDA's compounding advisory committee voted in July 2026 to recommend six peptide families for the 503A Bulks List. FDA has not published a proposed rule, and none of those substances appears on the final list at 21 CFR 216.23. We update this page when that changes.

The short answer, by pathway

No official federal list of "legal peptides" exists. Legality attaches to a product, a source, and an intended use, so two vials of the same molecule can sit on opposite sides of the line.

Where the most-asked peptides stand

The six peptides patients ask about most, as of October 5, 2026:

Any row can change with a single FDA notice. Check the date above and FDA's current category list before relying on it.

FDA-approved peptide drugs

The clearest legal ground is an FDA-approved drug. Peptide medicines have been part of ordinary practice for decades: insulin, oxytocin, leuprolide, octreotide, teriparatide, and the GLP-1 receptor agonists semaglutide, liraglutide, and tirzepatide are all peptide or peptide-based drugs with FDA approval for specific indications.

A licensed prescriber may prescribe an approved peptide drug for its labeled indication and, in most cases, off label. FDA regulates how drugs are marketed, and the decision to use an approved drug for an unapproved indication belongs to the practice of medicine. Off-label prescribing still carries the ordinary duties of informed consent, documentation, and a standard of care the clinician can defend.

There is one important exception, covered in the controlled substance section below: growth hormone.

Compounded peptides: 503A and 503B

Compounding is the second legal pathway, and the one where most of the confusion sits. A compounded drug is prepared by a pharmacy for a patient whose needs an approved product does not meet. Compounded drugs are not FDA-approved, and FDA does not review them for safety or effectiveness before they are dispensed.

Under Section 503A, a state-licensed pharmacy or physician may compound for an identified patient on a valid prescription. When the pharmacy starts from a bulk drug substance, that substance has to meet one of three conditions: it is covered by a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. A 503A pharmacy also may not regularly compound what are essentially copies of a commercially available drug. That rule is why compounded semaglutide and tirzepatide largely left the market after FDA declared their shortages resolved in February 2025 and December 2024.

Section 503B covers outsourcing facilities. These register with FDA, follow current good manufacturing practice, and may supply office stock without a patient-specific prescription. They work from their own bulks list and from FDA's drug shortage list.

How FDA's categories fit in

For substances nominated to the 503A Bulks List but not yet decided, FDA has used interim categories. Category 1 substances are under evaluation, and FDA has generally not taken action against pharmacies that compound with them while other conditions are met. Category 2 substances raised significant safety concerns in FDA's view. In 2023, FDA placed a group of popular peptides in Category 2, which effectively stopped 503A pharmacies from compounding them.

On April 15, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. Removal did not move them to Category 1 or onto the Bulks List. Law firms advising pharmacies describe these substances as sitting in a gray zone, with real enforcement risk for any pharmacy that treats removal as permission to compound.

The categories are an enforcement policy that FDA can revise at any time. Check the current FDA bulk substances page for a specific substance before relying on any secondhand list, including ours.

Research use only peptides

A large online market sells peptides labeled "research use only" or "not for human consumption." Selling these products for use in people violates federal drug law, and the label does not change that. FDA decides what a product is intended for from the whole context: dosing guidance, before-and-after claims, syringes sold alongside, and how the seller talks to buyers.

FDA has said this directly. In a March 31, 2026 warning letter to one seller, the agency wrote that despite "Research Use Only" and "not intended for human consumption" statements on the labeling, "evidence obtained from your website establishes that your products are intended to be drugs for human use." It cited the products as unapproved new drugs. FDA published a set of these letters in April 2026 and five more on September 1, 2026, all to online peptide sellers.

For clinicians, the consequence is simple. A research use only product cannot be prescribed, dispensed, or administered to a patient. When a patient is already using one, record it as a self-sourced exposure of unknown identity, purity, and sterility, and keep treating the underlying problem. Federal drug law is aimed mainly at the people who sell these products, which is why the warning letters go to sellers, but the patient bears the quality risk.

Peptides sold as supplements and cosmetics

Collagen peptides in a powder or capsule are a lawful food or dietary supplement. The supplement pathway has two limits that rule out most of what people mean by "peptide therapy."

First, a supplement must be intended for ingestion. An injectable product cannot be a dietary supplement. Second, the statutory definition excludes an ingredient that was approved as a drug, or studied as a drug in substantial public clinical investigations, before it was sold as a food or supplement. Several popular peptides fall on the drug side of that line.

Topical peptides in skin care are generally regulated as cosmetics. A cosmetic that claims to treat a condition or change the structure or function of the body becomes a drug in FDA's eyes.

Are peptides controlled substances?

Generally, no. Peptides are not scheduled under the federal Controlled Substances Act, and there is no DEA schedule for them. That is also why the Ryan Haight Act's in-person exam rule for prescribing controlled substances by telehealth does not apply to most peptides. State telehealth law still does.

Growth hormone is the exception that matters. It is a protein hormone, often grouped with peptides in conversation, and it is not on a DEA schedule either. But 21 U.S.C. 333(e) makes it a felony to distribute growth hormone, or possess it with intent to distribute, for any use in people other than treating a disease or recognized condition that FDA has authorized and a physician has ordered. Off-label prescribing, which is routine for most drugs, is a federal crime for growth hormone.

Athletes face a separate rule. The World Anti-Doping Agency prohibited list bans peptide hormones, growth factors, and related substances at all times. A peptide can be legal to prescribe and still end a tested athlete's eligibility.

Are peptides being legalized?

Headlines about peptides "being legalized" refer to the July 23 and 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee. The committee voted to recommend six of seven peptide families it reviewed for the 503A Bulks List, against the recommendation of FDA staff. Our breakdown of that meeting covers each vote.

The vote is advisory. Adding a substance to the Bulks List takes notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule. As of this update FDA has published no proposed rule, and it is not required to follow the committee. FDA has said the committee will consider more peptides at a meeting expected by February 2027.

Listing would also make these peptides eligible for compounding only. It would not make them FDA-approved drugs, and it would not make research use only vials legal.

State rules on top of federal law

A state cannot make legal what federal law prohibits, but every state adds its own rules. Those rules cover who may prescribe, what counts as a valid patient relationship, how telehealth works, which pharmacies may ship into the state, and how medical spas operate. A product that clears federal law can still be prescribed or dispensed unlawfully under state law.

Florida

Florida has no peptide-specific statute. Peptide prescribing falls under the Florida Board of Medicine's general standards, and compounding falls under the Board of Pharmacy's rules, which follow the federal 503A and 503B framework. An out-of-state clinician treating Florida patients by telehealth must register under section 456.47 of the Florida Statutes, and a pharmacy shipping into Florida needs a nonresident pharmacy registration, plus a separate nonresident sterile compounding permit for injectables. A 2026 bill on compounded weight-loss drugs, SB 860, died in committee.

California

California's medical board treats prescribing without an appropriate prior examination and a medical indication as unprofessional conduct under Business and Professions Code section 2242. That standard applies to peptides as it does to any prescription drug, and the examination can occur by telehealth when the standard of care allows. Pharmacies outside California need a nonresident pharmacy license, and a separate nonresident sterile compounding license to ship injectables in. California's ban on the corporate practice of medicine also shapes how a clinic or med spa offering peptides may be owned.

Texas

In Texas, physicians who delegate prescribing to nurse practitioners or physician assistants do so under the Texas Medical Board's delegation rules in Chapter 157 of the Occupations Code. Texas House Bill 3749, effective September 1, 2025, regulates elective IV therapy outside physician offices and licensed facilities, which reaches many med spas that also offer peptides. Out-of-state pharmacies need a Texas nonresident pharmacy license to dispense to Texas patients.

Other states

State activity is accelerating. Indiana enacted Senate Bill 282 in March 2026, which requires medical spas to register with the state's Medical Licensing Board starting January 1, 2027 and to report serious adverse events. Expect more states to regulate med spas, IV therapy, and compounded drugs in 2027 sessions.

What to check before prescribing a peptide

Each prescription needs five questions answered, in this order.

1. The product. Name the exact molecule, salt form, and formulation. A familiar name on a vial is not enough.
2. The pathway. Decide whether this is an approved drug, a 503A or 503B compounded preparation, or something outside both. If it is outside both, stop.
3. The source. For compounding, verify the pharmacy's license in your patient's state, its inspection history, and where its active ingredient comes from. A certificate of analysis covers one lot of raw material and says nothing about the sterility of the finished product.
4. Your scope. Confirm that your license, your state's telehealth rules, and any delegation or supervision agreement cover this prescription.
5. The record. Document the indication, the evidence discussed, the regulatory status, the source, and the patient's consent to the uncertainty.

Frequently asked questions

Is it legal to buy peptides online?

It is legal to fill a valid prescription through a licensed online pharmacy. Buying research use only peptides for personal injection sits outside every lawful pathway: the sellers are violating federal drug law, and FDA's warning letters target them for it. A buyer receives a product with no assurance of identity, purity, or sterility.

Can nurse practitioners and physician assistants prescribe peptides?

Usually, within their state's scope of practice rules. Approved and compounded peptides are prescription drugs, so the same authority that lets an NP or PA prescribe other prescription drugs applies, along with any supervision or collaboration agreement the state requires.

What changed for peptides in 2026?

Three things: FDA removed 12 peptides from Category 2 in April without adding them to the Bulks List, its advisory committee recommended six peptide families for the Bulks List in July, and FDA kept issuing warning letters to research use only sellers. None of these changed what a clinician may lawfully prescribe today.